APH vs. BXP, AGY, ANCR, BMK, CEL, EAH, OXB, HVO, AVCT, and TSTL
Should you be buying Alliance Pharma stock or one of its competitors? The main competitors of Alliance Pharma include Beximco Pharmaceuticals (BXP), Allergy Therapeutics (AGY), Animalcare Group (ANCR), Benchmark (BMK), Celadon Pharmaceuticals (CEL), ECO Animal Health Group (EAH), Oxford Biomedica (OXB), hVIVO (HVO), Avacta Group (AVCT), and Tristel (TSTL). These companies are all part of the "medical" sector.
Beximco Pharmaceuticals (LON:BXP) and Alliance Pharma (LON:APH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.
Beximco Pharmaceuticals has higher revenue and earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Beximco Pharmaceuticals and Beximco Pharmaceuticals both had 1 articles in the media. Alliance Pharma's average media sentiment score of 0.00 equaled Beximco Pharmaceuticals'average media sentiment score.
Beximco Pharmaceuticals pays an annual dividend of GBX 3 per share and has a dividend yield of 8.2%. Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 5.7%. Beximco Pharmaceuticals pays out 3,750.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Alliance Pharma pays out -20,000.0% of its earnings in the form of a dividend.
Beximco Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Alliance Pharma has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
Alliance Pharma has a consensus price target of GBX 80.75, indicating a potential upside of 131.38%. Given Beximco Pharmaceuticals' higher probable upside, analysts clearly believe Alliance Pharma is more favorable than Beximco Pharmaceuticals.
Alliance Pharma received 95 more outperform votes than Beximco Pharmaceuticals when rated by MarketBeat users. However, 64.67% of users gave Beximco Pharmaceuticals an outperform vote while only 62.08% of users gave Alliance Pharma an outperform vote.
1.6% of Beximco Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.0% of Alliance Pharma shares are owned by institutional investors. 11.7% of Alliance Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Beximco Pharmaceuticals has a net margin of 11.80% compared to Beximco Pharmaceuticals' net margin of -4.15%. Alliance Pharma's return on equity of 10.29% beat Beximco Pharmaceuticals' return on equity.
Summary
Beximco Pharmaceuticals beats Alliance Pharma on 10 of the 17 factors compared between the two stocks.
Get Alliance Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for APH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alliance Pharma Competitors List
Related Companies and Tools
